J Clin Psychopharmacol

Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression: A Real-World Cohort Study.

J Clin Psychopharmacol July 28, 2026

Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression: A Real-World Cohort Study.

DOI: 10.1097/jcp.0000000000002228 (opens in new tab)

Esketamine and Quality of Life Improvement in Treatment-Resistant Depression Patients: A Real-World Clinical Study.

J Clin Psychopharmacol November 21, 2025

Esketamine and Quality of Life Improvement in Treatment-Resistant Depression Patients: A Real-World Clinical Study.

DOI: 10.1097/jcp.0000000000002042 (opens in new tab)

Melatonin-Responsive Hypnagogic Hallucinations in a Patient With Bipolar Disorder and Posttraumatic Stress Disorder.

J Clin Psychopharmacol July 1, 2021

Melatonin-Responsive Hypnagogic Hallucinations in a Patient With Bipolar Disorder and Posttraumatic Stress Disorder.

DOI: 10.1097/jcp.0000000000001408 (opens in new tab)

Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration.

J Clin Psychopharmacol August 1, 2008

Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration.

DOI: 10.1097/jcp.0b013e31817ef470 (opens in new tab) Full text (opens in new tab)

Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence.

J Clin Psychopharmacol June 1, 1993

Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence.

DOI: 10.1097/00004714-199306000-00011 (opens in new tab)